A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. Academic Article uri icon

Overview

abstract

  • PURPOSE OF INVESTIGATION: To determine the effect of imatinib on progression-free survival in patients with epithelial ovarian cancer in second or greater complete clinical remission (CCR). METHODS: 35 patients were enrolled between 10/2002 and 1/2005. Eligible patients received imatinib at 400 mg daily orally. RESULTS: One patient withdrew consent, and two patients received protocol therapy in first remission and were excluded. Five patients were removed for possibly related toxicity. No associations were seen between PDGF-R staining and PFS. CONCLUSIONS: Treatment with imatinib for patients with ovarian cancer in second CCR or greater did not prolong the PFS beyond the historical estimate.

publication date

  • January 1, 2008

Research

keywords

  • Fallopian Tube Neoplasms
  • Neoplasm Recurrence, Local
  • Neoplasms, Glandular and Epithelial
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines

Identity

Scopus Document Identifier

  • 56749138439

PubMed ID

  • 19115680

Additional Document Info

volume

  • 29

issue

  • 6